Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.
Control of hyperphosphatemia and the administration of vitamin D are the primary treatment modalities for the prevention and management of secondary hyperparathyroidism. Vitamin D therapy for secondary hyperparathyroidism has been limited by the development of hypercalcemia and/or hyperphosphatemia due to increased intestinal absorption of these minerals. Recently, selective vitamin D analogs specifically designed to suppress parathyroid hormone (PTH) without causing hypercalcemia or hyperphosphatemia have shown promise for the treatment of secondary hyperparathyroidism in uremia. This case report describes the successful use of doxercalciferol to treat severe secondary hyperparathyroidism in an adult male patient undergoing chronic peritoneal dialysis, with a follow-up period of 9 months. During this period, the patient's hyperparathyroidism was rapidly and easily controlled. Treatment was complicated by a single incident of over suppression of PTH, with concomitant hypercalcemia. This quickly resolved upon temporary discontinuation of doxercalciferol therapy, after which therapy was resumed without further incident.
Sprague
S M
SM
ssprague@northwestern.edu
Ho
L T
LT
D000284:Administration, Oral; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004872:Ergocalciferols / Q000008:administration & dosage*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D010530:Peritoneal Dialysis
D004872:Ergocalciferols; D010281:Parathyroid Hormone; C042533:1 alpha-hydroxyergocalciferol